Lipid-lowering treatment and low-density lipoprotein cholesterol target achievement in patients with type 2 diabetes and acute coronary syndrome

Autor: Dominik Lautsch, Carl A. Baxter, Anselm K. Gitt, Peter P. Toth, Gaetano M. De Ferrari, Baishali M. Ambegaonkar, Kian Keong Poh, Jean Ferrières, Peter Bramlage, Martin Horack
Přispěvatelé: Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Hôpital de Rangueil, CHU Toulouse [Toulouse], Merck & Co. Inc, Johns Hopkins University School of Medicine [Baltimore], National University Health System [Singapore] (NUHS), Yong Loo Lin School of Medicine [Singapore], University of Pavia, Klinikum Ludwigshafen [Germany], Department of Molecular Medicine, Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome]-Institut Pasteur, Fondation Cenci Bolognetti - Istituto Pasteur Italia, Fondazione Cenci Bolognetti, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Male
[SDV]Life Sciences [q-bio]
Type 2 diabetes
030204 cardiovascular system & hematology
Gastroenterology
chemistry.chemical_compound
0302 clinical medicine
Patient Admission
Risk Factors
030212 general & internal medicine
Longitudinal Studies
medicine.diagnostic_test
Diabetes
General Medicine
Middle Aged
Lipids
3. Good health
Treatment Outcome
lipids (amino acids
peptides
and proteins)
Female
Acute coronary syndrome
Cardiology and Cardiovascular Medicine
medicine.medical_specialty
Statin
medicine.drug_class
Cholestérol des lipoprotéines de basse densité
Diabète
Statines
03 medical and health sciences
Hyperlipidaemia
Low-density lipoprotein cholesterol
Statins
Internal medicine
Diabetes mellitus
medicine
Potency
Humans
Aged
Dyslipidemias
Triglyceride
business.industry
Type 2 Diabetes Mellitus
medicine.disease
chemistry
Diabetes Mellitus
Type 2
Hydroxymethylglutaryl-CoA Reductase Inhibitors
business
Lipid profile
Syndrome coronarien aigu
Biomarkers
Hyperlipidémie
Zdroj: Archives of cardiovascular diseases
Archives of cardiovascular diseases, Elsevier/French Society of Cardiology, 2020, 113, pp.617-629. ⟨10.1016/j.acvd.2020.05.013⟩
ISSN: 1875-2136
DOI: 10.1016/j.acvd.2020.05.013⟩
Popis: International audience; Background: Patients with type 2 diabetes mellitus characteristically display an atherogenic lipid profile with high triglyceride concentrations, low high-density lipoprotein cholesterol (HDL-C) concentrations and low-density lipoprotein cholesterol (LDL-C) concentrations not always elevated. It is unclear if patients with diabetes who present with an acute coronary syndrome (ACS) receive different or more-potent lipid-lowering therapy (LLT).Aims: To investigate lipid abnormalities in patients with and without type 2 diabetes hospitalised for an ACS, and use of LLT before admission and 4 months after the event.Methods: Patients were included in the observational DYSIS II study if they were hospitalised for an ACS and had a full lipid profile.Results: Of 3803 patients, diabetes was documented in 1344 (54.7%). Compared to patients without diabetes, those with diabetes had a lower mean LDL-C (101.2 vs. 112.0mg/dL; 2.6 vs. 2.9mmol/L; P
Databáze: OpenAIRE
Externí odkaz: